Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.3042
+$0.0052 · +1.74%
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Previous close
$0.3042
+$0.0052 · +1.74%
After-hours
$0.3009
−$0.0033 · -1.08%
Oct 9, 6:49 PM ET
Regular session · ET · Market data may be delayed.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Day range
Current $0.3042
52-week range
Current $0.3042
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
47
Mixed
Risk
75
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Day range
Current $0.3042
52-week range
Current $0.3042
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 31.86M USD | 22.7M USD | 17.78M USD | 7.09M USD | 3.81M USD |
| Selling, general, and administrative | 7.85M USD | 7.22M USD | 7.29M USD | 7.79M USD | 3.63M USD |
| Operating expenses | 39.7M USD | 29.92M USD | 25.07M USD | 15.38M USD | 10.53M USD |
| Interest income | 3.38M USD | 3.2M USD | 1.16M USD | 547.27K USD | 64.24 USD |
| Interest expense | — | — | — | 547.27K USD | 64.24K USD |
| Depreciation and amortization | 16.25K USD | 10.88K USD | 12.04K USD | 9.27K USD | −3.09M USD |
| Operating income | −39.7M USD | −29.92M USD | −25.07M USD | −15.38M USD | −10.53M USD |
| Net income | −36.12M USD | −26.73M USD | −23.96M USD | −14.84M USD | −10.46M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.25
1625.84% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.1M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM711.79K0.00%78.27B USD0.19%$278.94+0.49%
iShares Russell 2000 Growth ETFIWO260.59K0.00%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO210.63K0.00%18B USD0.06%$112.66+0.50%
Vanguard Extended Market ETFVXF203.03K0.00%95.4B USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC88.7K0.01%1.32B USD0.60%$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG39.37K0.00%1.7B USD0.06%$260.49+0.91%
iShares Russell 2500 ETFSMMD15.01K0.00%4.03B USD0.23%$86.29+0.38%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
